Generic Drugs

Generic Drugs


Global Generic Drugs Market to Reach US$671.5 Billion by 2030

The global market for Generic Drugs estimated at US$430.2 Billion in the year 2023, is expected to reach US$671.5 Billion by 2030, growing at a CAGR of 6.6% over the analysis period 2023-2030. Small-Molecule Generics, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$538.8 Billion by the end of the analysis period. Growth in the Biosimilars segment is estimated at 17.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$130.2 Billion While China is Forecast to Grow at 8.2% CAGR

The Generic Drugs market in the U.S. is estimated at US$130.2 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$126.8 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.8% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR.

Global Generic Drugs Market - Key Trends & Drivers Summarized

Generic drugs play a pivotal role in the healthcare industry by providing cost-effective alternatives to brand-name medications. These drugs contain the same active ingredients, dosage form, strength, route of administration, and therapeutic effects as their branded counterparts, ensuring they are equally safe and effective. The production of generic drugs becomes possible after the patent protections on brand-name drugs expire, allowing other manufacturers to create and market the same medication at a lower price. The rigorous approval process for generics, overseen by regulatory bodies such as the U.S. Food and Drug Administration (FDA), ensures that these drugs meet stringent standards for quality, performance, and labeling.

The widespread use of generic drugs has significant implications for both healthcare systems and patients. By offering more affordable options, generics help to reduce the overall cost of healthcare, making medications more accessible to a larger portion of the population. This affordability can lead to improved adherence to treatment regimens, as patients are less likely to skip doses or abandon treatment due to high costs. Moreover, the increased availability of generic drugs fosters competition in the pharmaceutical market, which can drive down prices even further. Hospitals, insurance companies, and government healthcare programs heavily rely on generic drugs to manage budgets and provide comprehensive care to patients.

The growth in the generic drugs market is driven by several factors. Firstly, the rising incidence of chronic diseases and an aging population increase the demand for various medications, many of which are available as generics. The expiration of patents on several high-revenue drugs opens the door for generic manufacturers to introduce cost-effective alternatives. Additionally, technological advancements in pharmaceutical manufacturing enhance the efficiency and cost-effectiveness of producing generic drugs. Regulatory initiatives aimed at speeding up the approval process for generics and biosimilars also play a crucial role in market expansion. Consumer behavior trends, such as increased trust in generic medications and a greater focus on reducing healthcare expenditures, further propel market growth. Lastly, emerging markets with growing healthcare needs and improving healthcare infrastructure present new opportunities for generic drug manufacturers. These factors collectively drive the robust growth and adoption of generic drugs globally.

Select Competitors (Total 255 Featured) -
  • Abbott Laboratories
  • Apotex Inc.
  • ASKA Pharmaceutical Co., Ltd.
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca Plc
  • Baxter International Inc.
  • Dr. Reddy’s Laboratories Limited`
  • Eli Lilly and Company
  • Endo International plc
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi AG
  • GSK plc
  • H. Lundbeck A/S
  • Incepta Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Novo Nordisk A/S
  • Sandoz International GmbH
  • Sanofi-Aventis U.S. LLC
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Global Economic Update
Demand for Generic Pain Killers Rises
A Prelude to Generic Drugs
Generic Drugs Market Set for a Rapid Growth
North America and Europe Dominate, Asia-Pacific to Exhibit the Fastest Growth
India- A Significant Market
Small-molecule Generic Drugs Account for a Lion's Share, Biosimilars Exhibit Fastest Growth
Exciting Times for Biosimilars
Competition
Generic Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
Market Opportunities
Strategies to Sustain Success
The Future of Generics & Biosimilars Look Bright amid Persistent Barriers
Market Challenges
Factors Affecting Prices & Accessibility
Recent Market Activity
BRANDS
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Generic Drugs Enjoy Adrenaline Rush with Regulatory & Scientific Support
R&D & Innovation Push
Efforts to Eliminate Barriers to Generics Development
Regulatory & Scientific Collaboration as Key
FDA's Generic Drug User Free Program
Policy Support to Generic Drugs: Clearing Road to Affordable Access to Quality Medicines
Savings in Billions
Taking GDUFA to Next Level
Pushing Competition through ANDAs
Patent Expiries Set to Widen the Addressable Market for Generic Drugs
Patent Expiries of Select Drugs in 2020
Patent Expiries of Select Drugs in 2021
Patent Expiries of Select Drugs in 2022
Patent Expiries of Select Drugs in 2023
Patent Expiry of Select Major Drugs in the US: 2020-2023
Robust Demand for Pharmaceutical Drugs Drives Demand for Generic Drugs
Cost Containment Measures Put Focus on Generics
Small Molecule Generics Represent the Dominant Segment
Specialty Generic Drugs Gain Popularity
Specialty Generics - The Way to Success Amid Challenges
Factors that can Provide Competitive Edge
Increasing Demand for Biosimilars, Driven by Patent Expiry of Major Biopharmaceutical Drugs
Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe in the Recent Past
Progressive Regulatory Framework Accelerates Product Approvals & Subsequently Market Revenues
Specific Guidelines for Biosimilars in Various Countries with Year of Publication
Biosimilars Regulatory Agencies in Select Regional Markets
Biosimilar Approvals in the US (as of 2023)
Biosimilar Approvals in Europe (as of 2023)
Rising Healthcare Costs Drive Demand for Generic Drugs
World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
Aging Population to Propel the Demand for Generic Drugs
Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
Significant Increase in Number of Patients Suffering from Chronic Diseases Fuel Demand for Generic Medicines
Global Cost of Chronic Diseases (In US$ Billion) for the Years 2018 and 2030
Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
Number of New Cancer Cases and Deaths (in Million) by Region for 2018
US Regulators Struggle to Keep Up with the Global Market
Increased Dependency on Non-US Manufacturers
Patient Trust and Traceability
Drug Supply Shortage Risks
Fixing a Broken System
Hospitals Teaming Up to Develop Own Generic Drugs to Combat Shortages and High Prices
Use of Artificial Intelligence and Machine Learning in Pharmaceutical Manufacturing Witnesses a Surge
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Generic Drugs Market Analysis of Annual Sales in US$ Million for Years 2018 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 4: World 12-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2018, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Small-Molecule Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Small-Molecule Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 7: World 12-Year Perspective for Small-Molecule Generics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 10: World 12-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 13: World 12-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Central Nervous System (CNS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Central Nervous System (CNS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 16: World 12-Year Perspective for Central Nervous System (CNS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Dermatology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Dermatology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 19: World 12-Year Perspective for Dermatology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 22: World 12-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 25: World 12-Year Perspective for Respiratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Other Therapeutic Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Other Therapeutic Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 28: World 12-Year Perspective for Other Therapeutic Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2024 & 2030
A Prelude to Generic Drugs
III. MARKET ANALYSIS
UNITED STATES
Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 29: USA Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: USA Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 31: USA 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 32: USA Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: USA Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 34: USA 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
CANADA
Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Canada for 2023 (E)
TABLE 35: Canada Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 37: Canada 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 38: Canada Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 40: Canada 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
JAPAN
Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 41: Japan Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 43: Japan 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 44: Japan Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Japan Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 46: Japan 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
CHINA
Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 47: China Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: China Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 49: China 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 50: China Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: China Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 52: China 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
EUROPE
Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 53: Europe Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Generic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 55: Europe 12-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2018, 2024 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 58: Europe 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 59: Europe Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Europe Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 61: Europe 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
FRANCE
Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 62: France Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: France Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 64: France 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 65: France Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: France Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 67: France 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
GERMANY
Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 68: Germany Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 70: Germany 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 71: Germany Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Germany Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 73: Germany 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
ITALY
TABLE 74: Italy Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 76: Italy 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 77: Italy Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Italy Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 79: Italy 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
UNITED KINGDOM
Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 80: UK Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: UK Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 82: UK 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 83: UK Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: UK Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 85: UK 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
SPAIN
TABLE 86: Spain Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 88: Spain 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 89: Spain Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Spain Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 91: Spain 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
RUSSIA
TABLE 92: Russia Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 94: Russia 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 95: Russia Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Russia Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 97: Russia 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
REST OF EUROPE
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 100: Rest of Europe 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Rest of Europe Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 103: Rest of Europe 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
ASIA-PACIFIC
Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Generic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 106: Asia-Pacific 12-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2018, 2024 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 109: Asia-Pacific 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Asia-Pacific Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 112: Asia-Pacific 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
AUSTRALIA
Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 113: Australia Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Australia Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 115: Australia 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 116: Australia Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: Australia Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 118: Australia 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
INDIA
Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 119: India Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: India Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 121: India 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 122: India Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: India Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 124: India 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
SOUTH KOREA
TABLE 125: South Korea Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 127: South Korea 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 128: South Korea Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: South Korea Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 130: South Korea 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 133: Rest of Asia-Pacific 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: Rest of Asia-Pacific Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 136: Rest of Asia-Pacific 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
LATIN AMERICA
Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 137: Latin America Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Generic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 139: Latin America 12-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2018, 2024 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 142: Latin America 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 143: Latin America Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Latin America Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 145: Latin America 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
ARGENTINA
TABLE 146: Argentina Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 148: Argentina 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 149: Argentina Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Argentina Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 151: Argentina 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
BRAZIL
TABLE 152: Brazil Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 154: Brazil 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 155: Brazil Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Brazil Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 157: Brazil 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
MEXICO
TABLE 158: Mexico Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 160: Mexico 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 161: Mexico Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Mexico Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 163: Mexico 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
REST OF LATIN AMERICA
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 166: Rest of Latin America 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 168: Rest of Latin America Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 169: Rest of Latin America 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
MIDDLE EAST
Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 170: Middle East Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Generic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 172: Middle East 12-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2018, 2024 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 175: Middle East 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 176: Middle East Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: Middle East Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 178: Middle East 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
IRAN
TABLE 179: Iran Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: Iran Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 181: Iran 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 182: Iran Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: Iran Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 184: Iran 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
ISRAEL
TABLE 185: Israel Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: Israel Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 187: Israel 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 188: Israel Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: Israel Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 190: Israel 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
SAUDI ARABIA
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 193: Saudi Arabia 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: Saudi Arabia Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 196: Saudi Arabia 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 197: UAE Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: UAE Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 199: UAE 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 200: UAE Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: UAE Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 202: UAE 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
REST OF MIDDLE EAST
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 205: Rest of Middle East 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 207: Rest of Middle East Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 208: Rest of Middle East 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
AFRICA
Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 209: Africa Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 210: Africa Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 211: Africa 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2024 & 2030
TABLE 212: Africa Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 213: Africa Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
TABLE 214: Africa 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings